up-to-date with a click!
Update - October, 2017
 
Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.
The IAS Statin Newsletter will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Statin publications October 2017

Other

  1. Singh SP, Sashidhara KV. Lipid lowering agents of natural origin: An account of some promising chemotypes. European journal of medicinal chemistry 2017; 140:331-348. http://www.ncbi.nlm.nih.gov/pubmed/?term=28987600
  2. Zhang L, Wang X, Wang M et al. Circulating Cholesterol Levels May Link to the Factors Influencing Parkinson's Risk. Frontiers in neurology 2017; 8:501. http://www.ncbi.nlm.nih.gov/pubmed/?term=29021777
  3. van Giessen A, de Wit GA, Moons KGM et al. Rethinking optimization methods identified optimal risk thresholds for preventive treatment: an illustration in coronary heart disease. J Clin Epidemiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28986242
  4. Robinson T, Jackson R, Wells S et al. An observational study of how clinicians use cardiovascular risk assessment to inform statin prescribing decisions. The New Zealand medical journal 2017; 130:28-38. http://www.ncbi.nlm.nih.gov/pubmed/?term=28981492

Add on treatments

  1. Taylor BA. Does Coenzyme Q10 Supplementation Mitigate Statin-Associated Muscle Symptoms? Pharmacological and Methodological Considerations. Am J Cardiovasc Drugs 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29027135
  2. Hassan SMS, Razzaque A, Ahmad Z et al. Does posttreatment thymoquinone reverse high-dose, atorvastatin-induced hepatic oxidative injury in rats? Canadian journal of physiology and pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28968507
  3. Murasato Y, Kinoshita Y, Yamawaki M et al. Effect of low-density lipoprotein cholesterol on the geometry of coronary bifurcation lesions and clinical outcomes of coronary interventions in the J-REVERSE registry. Cardiovascular intervention and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29052106
  4. Erlandson KM, Kitch D, Wester WC et al. The Impact of Statin and ACE-inhibitor/Angiotensin Receptor Blocker Therapy on Cognitive Function in Adults with HIV Infection. Clin Infect Dis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29020174
  5. Bergland Ellingsen S, Nordmo E, Tore Lappegard K. Recurrence and Severe Worsening of Hepatotoxicity After Reintroduction of Atorvastatin in Combination With Ezetimibe. Clinical medicine insights. Case reports 2017; 10:1179547617731375. http://www.ncbi.nlm.nih.gov/pubmed/?term=28979175
  6. Abd El Aal HA, Ahmed LA, Hassan WA et al. Combination of carvacrol with simvastatin improves the lipid-lowering efficacy and alleviates simvastatin side effects. Journal of biochemical and molecular toxicology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29071762
  7. Chastain DB, Stover KR, Riche DM. Evidence-based review of statin use in patients with HIV on antiretroviral therapy. Journal of clinical & translational endocrinology 2017; 8:6-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=29067253
  8. Haywood LJ, Davis BR, Piller LB et al. Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT. Journal of the National Medical Association 2017; 109:172-181. http://www.ncbi.nlm.nih.gov/pubmed/?term=28987246
  9. Schaffer AL, Buckley NA, Pearson SA. Who benefits from fixed-dose combinations? Two-year statin adherence trajectories in initiators of combined amlodipine/atorvastatin therapy. Pharmacoepidemiol Drug Saf 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=2906775

Adherence

  1. Booth JN, 3rd, Colantonio LD, Chen L et al. Statin Discontinuation, Reinitiation, and Persistence Patterns Among Medicare Beneficiaries After Myocardial Infarction: A Cohort Study. Circ Cardiovasc Qual Outcomes 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=29021332
  2. Barkas F, Elisaf M. National hyperlipidemia management policies improve lipid target attainment in clinical practice. Current medical research and opinion 2017:1-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29019423
  3. Stauffer ME, Hutson P, Kaufman AS, Morrison A. The Adherence Rate Threshold is Drug Specific. Drugs in R&D 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29076037
  4. Koskinas KC, Siontis GCM, Piccolo R et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29069377
  5. Webster R, Bullen C, Patel A et al. Impact of switching to polypill based therapy by baseline potency of medication: Post-hoc analysis of the SPACE Collaboration dataset. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28986058
  6. Hickson RP, Robinson JG, Annis IE et al. Changes in Statin Adherence Following an Acute Myocardial Infarction Among Older Adults: Patient Predictors and the Association With Follow-Up With Primary Care Providers and/or Cardiologists. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=29051213
  7. Franklin JM, Donneyong MM, Desai RJ et al. Variation in adherence to medications across the healthcare system in two comparative effectiveness research cohorts. Journal of comparative effectiveness research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29039693
  8. Vaidya K, Arnott C, Martinez GJ et al. Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome: A CT Coronary Angiography Study. JACC. Cardiovascular imaging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29055633
  9. Schaffer AL, Buckley NA, Pearson SA. Who benefits from fixed-dose combinations? Two-year statin adherence trajectories in initiators of combined amlodipine/atorvastatin therapy. Pharmacoepidemiol Drug Saf 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29067759

Atherosclerosis & Imaging

  1. Murasato Y, Kinoshita Y, Yamawaki M et al. Effect of low-density lipoprotein cholesterol on the geometry of coronary bifurcation lesions and clinical outcomes of coronary interventions in the J-REVERSE registry. Cardiovascular intervention and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29052106
  2. Drakopoulou M, Toutouzas K, Michelongona A, Tousoulis D. Statins and vulnerable plaque. Current pharmaceutical design 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29065824
  3. Ceponiene I, Nakanishi R, Osawa K et al. Coronary Artery Calcium Progression Is Associated With Coronary Plaque Volume Progression: Results From a Quantitative Semiautomated Coronary Artery Plaque Analysis. JACC. Cardiovascular imaging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29055625
  4. Vaidya K, Arnott C, Martinez GJ et al. Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome: A CT Coronary Angiography Study. JACC. Cardiovascular imaging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29055633
  5. Hamilton-Craig CR, Chow CK, Younger JF et al. Cardiac Society of Australia and New Zealand position statement executive summary: coronary artery calcium scoring. Med J Aust 2017; 207:357-361. http://www.ncbi.nlm.nih.gov/pubmed/?term=29020908
 
 

Atorvastatin/Rosuvastatin

  1. Hileman CO, McComsey GA. The Effect of Rosuvastatin on Vascular Disease Differs by Smoking Status in Treated HIV-Infection. AIDS research and human retroviruses 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28974102
  2. Chiorescu S, Grad NO, Mironiuc IA, Andercou OA. Rosuvastatin administered intraperitoneally reduces the formation of postoperative adhesions in rats. Annali italiani di chirurgia 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28980533
  3. Betto M, Fares J, Saliba N, Ballout H. Efficacy and safety of a generic rosuvastatin in a real-world setting: prospective, observational clinical study in Lebanese patients. Annals of Saudi medicine 2017; 37:366-374. http://www.ncbi.nlm.nih.gov/pubmed/?term=28988251
  4. Santos C, Dourado DM, Silva B et al. ATORVASTATIN CAN PREVENT HEPATIC REMOTE REPERFUSION INJURY. Arq Bras Cir Dig 2017; 30:197-200. http://www.ncbi.nlm.nih.gov/pubmed/?term=29019561
  5. Chung CM, Lin MS, Chang CH et al. Moderate to high intensity statin in dialysis patients after acute myocardial infarction: A national cohort study in Asia. Atherosclerosis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28985950
  6. Dirajlal-Fargo S, El Kamari V, Sattar A et al. Effect of statin on arginine metabolites in treated HIV-infection. Atherosclerosis 2017; 266:74-80. http://www.ncbi.nlm.nih.gov/pubmed/?term=28992467
  7. Gumbiner B, Joh T, Liang H et al. The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Deltaa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies. Cardiovasc Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29078037
  8. Ekanayaka RA, Rupasinha AD, Sooriyarachchi MR, Goonaratna C. The effect of thriphala, a herbal Ayurveda formulation, on serum lipids, in patients on a maintenance dose of atorvastatin for hyperlipidaemia: a randomized controlled trial. The Ceylon medical journal 2017; 62:128-140. http://www.ncbi.nlm.nih.gov/pubmed/?term=29072054
  9. Bergland Ellingsen S, Nordmo E, Tore Lappegard K. Recurrence and Severe Worsening of Hepatotoxicity After Reintroduction of Atorvastatin in Combination With Ezetimibe. Clinical medicine insights. Case reports 2017; 10:1179547617731375. http://www.ncbi.nlm.nih.gov/pubmed/?term=28979175
  10. Uchida M, Tajima Y, Kakuni M et al. Organic anion transporting polypeptides (OATPs)-mediated drug-drug interaction study between rosuvastatin and cyclosporine A in chimeric mice with humanized liver. Drug metabolism and disposition: the biological fate of chemicals 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29051147
  11. Sathyapalan T, Coady AM, Kilpatrick E, Atkin S. The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine connections 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29018156
  12. Koskinas KC, Siontis GCM, Piccolo R et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29069377
  13. Hu X, Cheng J, Li C. Effects of rosuvastatin and atorvastatin on nonsustained ventricular tachycardia in patients with ST-elevation myocardial infarction: a retrospective analysis. Eur J Clin Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28965256
  14. Guo J, Zhang WZ, Zhao Q et al. Study on the effect of different doses of rosuvastatin on ventricular remodeling in patients with acute coronary syndrome after emergency percutaneous coronary intervention. Eur Rev Med Pharmacol Sci 2017; 21:4457-4463. http://www.ncbi.nlm.nih.gov/pubmed/?term=29077146
  15. Hirpara MR, Manikkath J, Sivakumar K et al. Long circulating PEGylated-chitosan nanoparticles of rosuvastatin calcium: Development and in vitro and in vivo evaluations. International journal of biological macromolecules 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29042279
  16. Shakir MKM, Shin T, Hoang TD, Mai VQ. Successful treatment of a patient with statin-induced myopathy and myotonic dystrophy type II with proprotein convertase subtilisin/kexin type 9 inhibitor, alirocumab (Praluent). J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29056268
  17. Chastain DB, Stover KR, Riche DM. Evidence-based review of statin use in patients with HIV on antiretroviral therapy. Journal of clinical & translational endocrinology 2017; 8:6-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=29067253
  18. Li Y, Jiang T, Fu X et al. [Retracted] Atorvastatin protects cardiomyocytes against OGD/Rinduced apoptosis by inhibiting miR199a5p. Mol Med Rep 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29039522
  19. Lu C, Jia H, Wang Z. High-dose atorvastatin reduces the risk of cardiovascular events in patients with percutaneous coronary intervention. Oncotarget 2017; 8:70356-70365. http://www.ncbi.nlm.nih.gov/pubmed/?term=29050285
  20. Rajput TA, Naveed AK, Farooqi ZR, Khan S. Effects of two functionally important SLCO1B1 gene polymorphisms on pharmacokinetics of atorvastatin. Pak J Pharm Sci 2017; 30:1363-1370. http://www.ncbi.nlm.nih.gov/pubmed/?term=29039339
  21. Leung YH, Turgeon J, Michaud V. Study of Statin- and Loratadine-Induced Muscle Pain Mechanisms Using Human Skeletal Muscle Cells. Pharmaceutics 2017; 9. http://www.ncbi.nlm.nih.gov/pubmed/?term=28994701
  22. Schaffer AL, Buckley NA, Pearson SA. Who benefits from fixed-dose combinations? Two-year statin adherence trajectories in initiators of combined amlodipine/atorvastatin therapy. Pharmacoepidemiol Drug Saf 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29067759
  23. Thongnak L, Pongchaidecha A, Jaikumkao K et al. The additive effects of atorvastatin and insulin on renal function and renal organic anion transporter 3 function in diabetic rats. Scientific reports 2017; 7:13532. http://www.ncbi.nlm.nih.gov/pubmed/?term=29051569
  24. Zhdan V, Khaymenova G, Shilkina L et al. Determine the effectiveness of lipid-lowering therapy in patients with chronic obstructive pulmonary disease combined with coronary heart disease. Wiadomosci lekarskie (Warsaw, Poland : 1960) 2017; 70:303-305. http://www.ncbi.nlm.nih.gov/pubmed/?term=29059648

Basic science

  1. Bao XC, Mao AR, Fang YQ et al. Simvastatin Decreases Hyperoxic Oxygen-Induced Acute Lung Injury by Upregulating eNOS. American journal of physiology. Lung cellular and molecular physiology 2017:ajplung.00520.02016. http://www.ncbi.nlm.nih.gov/pubmed/?term=29074491
  2. Chiorescu S, Grad NO, Mironiuc IA, Andercou OA. Rosuvastatin administered intraperitoneally reduces the formation of postoperative adhesions in rats. Annali italiani di chirurgia 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28980533
  3. Santos C, Dourado DM, Silva B et al. Atorvastatin can prevent hepatic remote reperfusion injury. Arq Bras Cir Dig 2017; 30:197-200. http://www.ncbi.nlm.nih.gov/pubmed/?term=29019561
  4. Lopez-Alvarez M, Lopez-Puente V, Rodriguez-Valencia C et al. Osteogenic effects of simvastatin-loaded mesoporous titania thin films. Biomedical materials (Bristol, England) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29068320
  5. Elmasry A, Aladeeb NM, Elkaref A, Aboulfotouh N. Simvastatin exerts antifibrotic effect and potentiates the antischistosomal effects of praziquantel in a murine model: Role of IL10. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2017; 96:215-221. http://www.ncbi.nlm.nih.gov/pubmed/?term=28987945
  6. Hassan SMS, Razzaque A, Ahmad Z et al. Does posttreatment thymoquinone reverse high-dose, atorvastatin-induced hepatic oxidative injury in rats? Canadian journal of physiology and pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28968507
  7. Varshosaz J, Taymouri S, Minaiyan M et al. Development and In vitro/in vivo evaluation of HPMC/chitosan gel containing simvastatin loaded self-assembled nanomicelles as a potent wound healing agent. Drug development and industrial pharmacy 2017:1-31. http://www.ncbi.nlm.nih.gov/pubmed/?term=29043860
  8. Zhang Y, Rong S, Feng Y et al. Simvastatin attenuates renal ischemia/reperfusion injury from oxidative stress via targeting Nrf2/HO-1 pathway. Experimental and therapeutic medicine 2017; 14:4460-4466. http://www.ncbi.nlm.nih.gov/pubmed/?term=29067120
  9. Wu X, Song M, Qiu P et al. A metabolite of nobiletin, 4'-demethylnobiletin and atorvastatin synergistically inhibits human colon cancer cell growth by inducing G0/G1 cell cycle arrest and apoptosis. Food & function 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29063088
  10. Wang Y, Yang W, Zhao X, Zhang R. Experimental Study of the Protective Effect of Simvastatin on Lung Injury in Rats with Sepsis. Inflammation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29022140
  11. Chang YL, Huang LC, Chen YC et al. The synergistic effects of valproic acid and fluvastatin on apoptosis induction in glioblastoma multiforme cell lines. The international journal of biochemistry & cell biology 2017; 92:155-163. http://www.ncbi.nlm.nih.gov/pubmed/?term=29017950
  12. Hirpara MR, Manikkath J, Sivakumar K et al. Long circulating PEGylated-chitosan nanoparticles of rosuvastatin calcium: Development and in vitro and in vivo evaluations. International journal of biological macromolecules 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29042279
  13. Tate R, Zona E, De Cicco R et al. Simvastatin inhibits the expression of stemnessrelated genes and the metastatic invasion of human cancer cells via destruction of the cytoskeleton. International journal of oncology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29039527
  14. Kong R, Zhu X, Meteleva ES et al. Enhanced solubility and bioavailability of simvastatin by mechanochemically obtained complexes. Int J Pharm 2017; 534:108-118. http://www.ncbi.nlm.nih.gov/pubmed/?term=28993167
  15. Abd El Aal HA, Ahmed LA, Hassan WA et al. Combination of carvacrol with simvastatin improves the lipid-lowering efficacy and alleviates simvastatin side effects. Journal of biochemical and molecular toxicology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29071762
  16. Han JS, Sung JH, Lee SK. Inhibition of Cholesterol Synthesis in HepG2 Cells by GINST-Decreasing HMG-CoA Reductase Expression Via AMP-Activated Protein Kinase. Journal of food science 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29065216
  17. Hubert S, Chadwick A, Wacher V et al. Development of a Modified Release Formulation of Lovastatin Targeted to Intestinal Methanogens Implicated in Irritable Bowel Syndrome with Constipation. Journal of pharmaceutical sciences 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28989013
  18. Li Y, Jiang T, Fu X et al. [Retracted] Atorvastatin protects cardiomyocytes against OGD/Rinduced apoptosis by inhibiting miR199a5p. Mol Med Rep 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29039522
  19. Tang FC, Wang HY, Ma MM et al. Simvastatin attenuated rat thoracic aorta remodeling by decreasing ROCK2mediated CyPA secretion and CD147ERK1/2cyclin pathway. Mol Med Rep 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28983618
  20. Wang Y, Chen Q, Tan Q et al. Simvastatin accelerates hematoma resolution after intracerebral hemorrhage in a PPARgamma-dependent manner. Neuropharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29054366
  21. Kobayashi Y, Kashima H, Rahmanto YS et al. Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer. Oncotarget 2017; 8:72147-72156. http://www.ncbi.nlm.nih.gov/pubmed/?term=29069775
  22. Leung YH, Turgeon J, Michaud V. Study of Statin- and Loratadine-Induced Muscle Pain Mechanisms Using Human Skeletal Muscle Cells. Pharmaceutics 2017; 9. http://www.ncbi.nlm.nih.gov/pubmed/?term=28994701
  23. Huang B, Zhou ZY, Li S et al. Tanshinone I prevents atorvastatin-induced cerebral hemorrhage in zebrafish and stabilizes endothelial cell-cell adhesion by inhibiting VE-cadherin internalization and actin-myosin contractility. Pharmacol Res 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29017932
  24. Thongnak L, Pongchaidecha A, Jaikumkao K et al. The additive effects of atorvastatin and insulin on renal function and renal organic anion transporter 3 function in diabetic rats. Scientific reports 2017; 7:13532. http://www.ncbi.nlm.nih.gov/pubmed/?term=29051569
  25. Fujiwara D, Tsubaki M, Takeda T et al. Statins induce apoptosis through inhibition of Ras signaling pathways and enhancement of Bim and p27 expression in human hematopoietic tumor cells. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2017; 39:1010428317734947. http://www.ncbi.nlm.nih.gov/pubmed/?term=28990465

Cancer

  1. Islam MM, Yang HC, Nguyen PA et al. Exploring association between statin use and breast cancer risk: an updated meta-analysis. Archives of gynecology and obstetrics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28940025
  2. Joo MK, Park JJ, Chun HJ. Additional Benefits of Routine Drugs on Gastrointestinal Cancer: Statins, Metformin, and Proton Pump Inhibitors. Dig Dis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28881340
  3. Karlic H, Haider F, Thaler R et al. Statin and Bisphosphonate Induce Starvation in Fast-Growing Cancer Cell Lines. Int J Mol Sci 2017; 18. http://www.ncbi.nlm.nih.gov/pubmed/?term=28914765
  4. Magan-Fernandez A, Fernandez-Barbero JE, F OV et al. Simvastatin exerts antiproliferative and differentiating effects on MG63 osteoblast-like cells: Morphological and immunocytochemical study. Journal of periodontal research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28868611
  5. Villarino N, Signaevskaia L, van Niekerk J et al. A screen for inducers of bHLH activity identifies pitavastatin as a regulator of p21, Rb phosphorylation and E2F target gene expression in pancreatic cancer. Oncotarget 2017; 8:53154-53167. http://www.ncbi.nlm.nih.gov/pubmed/?term=28881801
  6. Kang M, Lee KH, Lee HS et al. Concurrent treatment with simvastatin and NF-kappaB inhibitor in human castration-resistant prostate cancer cells exerts synergistic anti-cancer effects via control of the NF-kappaB/LIN28/let-7 miRNA signaling pathway. PLoS One 2017; 12:e0184644. http://www.ncbi.nlm.nih.gov/pubmed/?term=28910332
  7. Karagkounis G, DeVecchio J, Ferrandon S, Kalady MF. Simvastatin enhances radiation sensitivity of colorectal cancer cells. Surgical endoscopy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28916945

Children

  1. Ekici F, Ozcobanoglu S, Kardelen F. Premature Coronary Artery Disease due to Homozygous Familial Hypercholesterolemia in a 12-Year-old Girl. Balkan medical journal 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29072176
  2. Rong X, Yin J, Wang H et al. Statin treatment may lower the risk of postradiation epilepsy in patients with nasopharyngeal carcinoma. Epilepsia 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29034463
  3. Tremoulet AH. Adjunctive therapies in Kawasaki disease. International journal of rheumatic diseases 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29076637
  4. Buonuomo PS, Macchiaiolo M, Mastrogiorgio G et al. Statin-associated myopathy in pediatric settings: Myth or fact? J Pediatr 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28964429

Cost-effectiveness

  1. Stadler SL, Cook TJ. PCSK9 inhibitors and managing cost in the managed care setting. The American journal of managed care 2017; 23:S149-s155. http://www.ncbi.nlm.nih.gov/pubmed/?term=28978220
  2. Arrieta A, Hong JC, Khera R et al. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29049467

CVD

  1. Kilic S, Sumerkan MC, Emren V et al. Secondary prevention of coronary heart disease in elderly population of turkey: A subgroup analysis of ELDERTURK study. Cardiology journal 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28980279
  2. Szummer K, Wallentin L, Lindhagen L et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29020314
  3. Hu X, Cheng J, Li C. Effects of rosuvastatin and atorvastatin on nonsustained ventricular tachycardia in patients with ST-elevation myocardial infarction: a retrospective analysis. Eur J Clin Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28965256
  4. Kaiser P, Arnold AM, Benkeser D et al. Comparing methods to address bias in observational data: statin use and cardiovascular events in a US cohort. International journal of epidemiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29024975
  5. An J, Shi F, Liu S et al. Preoperative statins as modifiers of cardiac and inflammatory outcomes following coronary artery bypass graft surgery: a meta-analysis. Interact Cardiovasc Thorac Surg 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29049804
  6. Bayes-Genis A, Nunez J, Zannad F et al. The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIOSTAT-CHF Subanalysis. J Am Coll Cardiol 2017; 70:2128-2136. http://www.ncbi.nlm.nih.gov/pubmed/?term=29050560
  7. Kiyosue A. Nonfasting TG/HDL-C ratio seems a good predictor of MACE in CAD patients with statin therapy. Could it be a treatment target? J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29033056
  8. Haywood LJ, Davis BR, Piller LB et al. Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT. Journal of the National Medical Association 2017; 109:172-181. http://www.ncbi.nlm.nih.gov/pubmed/?term=28987246
  9. Sim DS, Jeong MH. Differences in the Korea Acute Myocardial Infarction Registry Compared with Western Registries. Korean Circ J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29035427
  10. Lu C, Jia H, Wang Z. High-dose atorvastatin reduces the risk of cardiovascular events in patients with percutaneous coronary intervention. Oncotarget 2017; 8:70356-70365. http://www.ncbi.nlm.nih.gov/pubmed/?term=29050285
  11. Myftiu S, Sulo E, Burazeri G et al. Clinical Profile and Management of Patients with Incident and Recurrent Acute Myocardial Infarction in Albania - a Call for More Focus on Prevention Strategies. Zdravstveno varstvo 2017; 56:236-243. http://www.ncbi.nlm.nih.gov/pubmed/?term=29062398

Endothelium/inflammation

  1. Marz W, Laufs U. Leucocyte immunoglobulin-like receptor subfamily-B5 (LILRB5) genetic variation and statin-associated muscle symptoms: another piece in a puzzling puzzle. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29059353

Ethnicity

  1. Murasato Y, Kinoshita Y, Yamawaki M et al. Effect of low-density lipoprotein cholesterol on the geometry of coronary bifurcation lesions and clinical outcomes of coronary interventions in the J-REVERSE registry. Cardiovascular intervention and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29052106
  2. Rostami Z, Moteshaker Arani M, Salesi M et al. Effect of Statins on Patients and Graft Survival in Kidney Transplant Recipients: a Survival Meta-analysis. Iran J Kidney Dis 2017; 11:329-338. http://www.ncbi.nlm.nih.gov/pubmed/?term=29038386
  3. Ofori S, Dodiyi-Manuel S, Akpa MR. Comparison of 3 risk estimators to guide initiation of statin therapy for primary prevention of cardiovascular disease. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29050979
  4. Endo A, Okada T, Pak M et al. Comparison of the low-density lipoprotein cholesterol target value and the preventive effect of statins in elderly patients and younger patients. Journal of geriatric cardiology : JGC 2017; 14:383-391. http://www.ncbi.nlm.nih.gov/pubmed/?term=29056945
  5. Sim DS, Jeong MH. Differences in the Korea Acute Myocardial Infarction Registry Compared with Western Registries. Korean Circ J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29035427
  6. Lu C, Jia H, Wang Z. High-dose atorvastatin reduces the risk of cardiovascular events in patients with percutaneous coronary intervention. Oncotarget 2017; 8:70356-70365. http://www.ncbi.nlm.nih.gov/pubmed/?term=29050285
  7. Rajput TA, Naveed AK, Farooqi ZR, Khan S. Effects of two functionally important SLCO1B1 gene polymorphisms on pharmacokinetics of atorvastatin. Pak J Pharm Sci 2017; 30:1363-1370. http://www.ncbi.nlm.nih.gov/pubmed/?term=29039339
  8. Myftiu S, Sulo E, Burazeri G et al. Clinical Profile and Management of Patients with Incident and Recurrent Acute Myocardial Infarction in Albania - a Call for More Focus on Prevention Strategies. Zdravstveno varstvo 2017; 56:236-243. http://www.ncbi.nlm.nih.gov/pubmed/?term=29062398

FH

  1. Amrock SM, Duell PB, Knickelbine T et al. Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH patient registry. Atherosclerosis 2017; 267:19-26. http://www.ncbi.nlm.nih.gov/pubmed/?term=29080546
  2. Ekici F, Ozcobanoglu S, Kardelen F. Premature Coronary Artery Disease due to Homozygous Familial Hypercholesterolemia in a 12-Year-old Girl. Balkan medical journal 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29072176
  3. Pang J, Hu M, Lin J et al. An enquiry based on a standardised questionnaire into knowledge, awareness and preferences concerning the care of familial hypercholesterolaemia among primary care physicians in the Asia-Pacific region: the "Ten Countries Study". BMJ Open 2017; 7:e017817. http://www.ncbi.nlm.nih.gov/pubmed/?term=29074516
  4. Ruel I, Aljenedil S, Sadri I et al. Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. Clinical chemistry 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29038147
  5. Drakopoulou M, Toutouzas K, Michelongona A, Tousoulis D. Statins and vulnerable plaque. Current pharmaceutical design 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29065824
  6. Vuorio A, Watts GF, Kovanen PT. Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a). Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29029165
  7. Defesche JC, Stefanutti C, Langslet G et al. Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28964736

Generics

  1. Betto M, Fares J, Saliba N, Ballout H. Efficacy and safety of a generic rosuvastatin in a real-world setting: prospective, observational clinical study in Lebanese patients. Annals of Saudi medicine 2017; 37:366-374. http://www.ncbi.nlm.nih.gov/pubmed/?term=28988251 

Genetics

  1. M KS, Maroteau C, Veluchamy A et al. A common missense variant of LILRB5 is associated with statin intolerance and myalgia. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29020356 

Guidelines

  1. Greenlee H, Strizich G, Lovasi GS et al. Concordance with prevention guidelines and subsequent cancer, cardiovascular disease, and mortality: A longitudinal study of older adults. American journal of epidemiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29020206
  2. Gitt AK, Lautsch D, Ferrieres J et al. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II. Atherosclerosis 2017; 266:158-166. http://www.ncbi.nlm.nih.gov/pubmed/?term=29028484
  3. Hawkes N. Statin initiation is unrelated to cardiovascular risk score, finds study. Bmj 2017; 359:j4898. http://www.ncbi.nlm.nih.gov/pubmed/?term=29066582
  4. Finnikin S, Ryan R, Marshall T. Statin initiations and QRISK2 scoring in UK general practice: a THIN database study. Br J Gen Pract 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29061715
  5. Leya M, Stone NJ. Statin Prescribing in the Elderly: Special Considerations. Curr Atheroscler Rep 2017; 19:47. http://www.ncbi.nlm.nih.gov/pubmed/?term=29019063
  6. Barkas F, Elisaf M. National hyperlipidemia management policies improve lipid target attainment in clinical practice. Current medical research and opinion 2017:1-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29019423
  7. Szummer K, Wallentin L, Lindhagen L et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29020314
  8. Schilling C, Knight J, Mortimer D et al. Australian general practitioners initiate statin therapy primarily on the basis of lipid levels; New Zealand general practitioners use absolute risk. Health Policy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29042060
  9. Ofori S, Dodiyi-Manuel S, Akpa MR. Comparison of 3 risk estimators to guide initiation of statin therapy for primary prevention of cardiovascular disease. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29050979
  10. Hamilton-Craig CR, Chow CK, Younger JF et al. Cardiac Society of Australia and New Zealand position statement executive summary: coronary artery calcium scoring. Med J Aust 2017; 207:357-361. http://www.ncbi.nlm.nih.gov/pubmed/?term=29020908
  11. Demirci D, Ersan Demirci D, Esin M et al. [Do Turkish reimbursement recommendations cover current European Lipid Guidelines? A retrospective analysis of patients presenting with first acute coronary syndrom]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2017; 45:623-629. http://www.ncbi.nlm.nih.gov/pubmed/?term=28990943

LDL- related parameters

  1. Ruel I, Aljenedil S, Sadri I et al. Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. Clinical chemistry 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29038147
  2. Vuorio A, Watts GF, Kovanen PT. Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a). Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29029165
  3. Schilling C, Knight J, Mortimer D et al. Australian general practitioners initiate statin therapy primarily on the basis of lipid levels; New Zealand general practitioners use absolute risk. Health Policy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29042060
  4. Yeh YT, Yin WH, Tseng WK et al. Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? Data from a multicenter registry cohort study in Taiwan. PLoS One 2017; 12:e0186861. http://www.ncbi.nlm.nih.gov/pubmed/?term=29073192

Meta-analyses

  1. Liu H, Xu X. Effect of simvastatin in patients with aneurysmal subarachnoid hemorrhage: A systematic review and meta-analysis. The American journal of emergency medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28966073
  2. Hutchinson J, Marignol L. Clinical Potential of Statins in Prostate Cancer Radiation Therapy. Anticancer research 2017; 37:5363-5372. http://www.ncbi.nlm.nih.gov/pubmed/?term=28982844
  3. An J, Shi F, Liu S et al. Preoperative statins as modifiers of cardiac and inflammatory outcomes following coronary artery bypass graft surgery: a meta-analysis. Interact Cardiovasc Thorac Surg 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29049804
  4. Rostami Z, Moteshaker Arani M, Salesi M et al. Effect of Statins on Patients and Graft Survival in Kidney Transplant Recipients: a Survival Meta-analysis. Iran J Kidney Dis 2017; 11:329-338. http://www.ncbi.nlm.nih.gov/pubmed/?term=29038386
  5. Toth PP, Worthy G, Gandra SR et al. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28971955
  6. Lu C, Jia H, Wang Z. High-dose atorvastatin reduces the risk of cardiovascular events in patients with percutaneous coronary intervention. Oncotarget 2017; 8:70356-70365. http://www.ncbi.nlm.nih.gov/pubmed/?term=29050285
  7. Yang J, Zhu Q, Liu Q et al. Statin use and endometrial cancer risk: a meta-analysis. Oncotarget 2017; 8:62425-62434. http://www.ncbi.nlm.nih.gov/pubmed/?term=28977956

Metabolic Syndrome - Diabetes

  1. Al-Salameh A, Bucher S, Bauduceau B et al. Gender-Related Differences in the Control of Cardiovascular Risk Factors in Primary Care for Elderly Patients with Type 2 Diabetes: A Cohort Study. Canadian journal of diabetes 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29037572
  2. Ebtehaj S, Gruppen EG, Parvizi M et al. The anti-inflammatory function of HDL is impaired in type 2 diabetes: role of hyperglycemia, paraoxonase-1 and low grade inflammation. Cardiovascular diabetology 2017; 16:132. http://www.ncbi.nlm.nih.gov/pubmed/?term=29025405
  3. Sathyapalan T, Coady AM, Kilpatrick E, Atkin S. The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine connections 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29018156

New Treatments

  1. Stadler SL, Cook TJ. PCSK9 inhibitors and managing cost in the managed care setting. The American journal of managed care 2017; 23:S149-s155. http://www.ncbi.nlm.nih.gov/pubmed/?term=28978220
  2. Fazio S, Robertson DG, Joh T et al. Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin. Cardiovasc Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29057618
  3. Gumbiner B, Joh T, Liang H et al. The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Deltaa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies. Cardiovasc Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29078037
  4. Tall AR, Rader DJ. The Trials and Tribulations of CETP Inhibitors. Circulation research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29018035
  5. Williams SA, Murthy AC, DeLisle RK et al. Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28974520
  6. El Khoury P, Elbitar S, Ghaleb Y et al. PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies. Curr Atheroscler Rep 2017; 19:49. http://www.ncbi.nlm.nih.gov/pubmed/?term=29038906
  7. Vuorio A, Watts GF, Kovanen PT. Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a). Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29029165
  8. Roth EM. A Safety Evaluation of Evolocumab. Expert opinion on drug safety 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28988500
  9. Bayes-Genis A, Nunez J, Zannad F et al. The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIOSTAT-CHF Subanalysis. J Am Coll Cardiol 2017; 70:2128-2136. http://www.ncbi.nlm.nih.gov/pubmed/?term=29050560
  10. Toth PP, Worthy G, Gandra SR et al. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28971955
  11. Defesche JC, Stefanutti C, Langslet G et al. Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28964736
  12. Shakir MKM, Shin T, Hoang TD, Mai VQ. Successful treatment of a patient with statin-induced myopathy and myotonic dystrophy type II with proprotein convertase subtilisin/kexin type 9 inhibitor, alirocumab (Praluent). J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29056268
  13. Rosenson RS, Larrey D, Waters DD, Olsson AG. RE: Praluent (Alirocumab)-Induced Renal Injury. Journal of pharmacy practice 2017:897190017734429. http://www.ncbi.nlm.nih.gov/pubmed/?term=28974137
  14. Arrieta A, Hong JC, Khera R et al. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29049467
  15. van de Borne P. [Recent progresses in the treatment of dyslipidemia]. Revue medicale de Bruxelles 2017; 38:357-360. http://www.ncbi.nlm.nih.gov/pubmed/?term=28981240

PAD and statins

  1. Balkanay OO, Omeroglu SN. [Approach to peripheral arterial disease in the elderly]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2017; 45:96-101. http://www.ncbi.nlm.nih.gov/pubmed/?term=28976393

Pleiotropic effects of statins

  1. Price JC, Tien PC. Editorial: Statins and Liver Disease: Is it Time to Recommend Statins to Prevent Liver Disease Progression? Am J Gastroenterol 2017; 112:1506-1507. http://www.ncbi.nlm.nih.gov/pubmed/?term=28978973
  2. Bao XC, Mao AR, Fang YQ et al. Simvastatin Decreases Hyperoxic Oxygen-Induced Acute Lung Injury by Upregulating eNOS. American journal of physiology. Lung cellular and molecular physiology 2017:ajplung.00520.02016. http://www.ncbi.nlm.nih.gov/pubmed/?term=29074491
  3. Santos C, Dourado DM, Silva B et al. Atorvastatin can prevent hepatic remote reperfusion injury. Arq Bras Cir Dig 2017; 30:197-200. http://www.ncbi.nlm.nih.gov/pubmed/?term=29019561
  4. Dirajlal-Fargo S, El Kamari V, Sattar A et al. Effect of statin on arginine metabolites in treated HIV-infection. Atherosclerosis 2017; 266:74-80. http://www.ncbi.nlm.nih.gov/pubmed/?term=28992467
  5. Lopez-Alvarez M, Lopez-Puente V, Rodriguez-Valencia C et al. Osteogenic effects of simvastatin-loaded mesoporous titania thin films. Biomedical materials (Bristol, England) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29068320
  6. Elmasry A, Aladeeb NM, Elkaref A, Aboulfotouh N. Simvastatin exerts antifibrotic effect and potentiates the antischistosomal effects of praziquantel in a murine model: Role of IL10. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2017; 96:215-221. http://www.ncbi.nlm.nih.gov/pubmed/?term=28987945
  7. Byrne DD, Tate JP, Forde KA et al. Risk of Acute Liver Injury After Statin Initiation by Human Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status. Clin Infect Dis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29020184
  8. Grudzinska FS, Dosanjh DP, Parekh D et al. Statin therapy in patients with community-acquired pneumonia. Clinical medicine (London, England) 2017; 17:403-407. http://www.ncbi.nlm.nih.gov/pubmed/?term=28974587
  9. Varshosaz J, Taymouri S, Minaiyan M et al. Development and In vitro/in vivo evaluation of HPMC/chitosan gel containing simvastatin loaded self-assembled nanomicelles as a potent wound healing agent. Drug development and industrial pharmacy 2017:1-31. http://www.ncbi.nlm.nih.gov/pubmed/?term=29043860
  10. Rong X, Yin J, Wang H et al. Statin treatment may lower the risk of postradiation epilepsy in patients with nasopharyngeal carcinoma. Epilepsia 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29034463
  11. Hu X, Cheng J, Li C. Effects of rosuvastatin and atorvastatin on nonsustained ventricular tachycardia in patients with ST-elevation myocardial infarction: a retrospective analysis. Eur J Clin Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28965256
  12. De Moreuil C, Le Mao R, Tromeur C et al. Association between statin exposure and venous thromboembolism risk in cancer patients. Data from the EDITH case-control study. Eur J Intern Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29046258
  13. Guo J, Zhang WZ, Zhao Q et al. Study on the effect of different doses of rosuvastatin on ventricular remodeling in patients with acute coronary syndrome after emergency percutaneous coronary intervention. Eur Rev Med Pharmacol Sci 2017; 21:4457-4463. http://www.ncbi.nlm.nih.gov/pubmed/?term=29077146
  14. Zhang Y, Rong S, Feng Y et al. Simvastatin attenuates renal ischemia/reperfusion injury from oxidative stress via targeting Nrf2/HO-1 pathway. Experimental and therapeutic medicine 2017; 14:4460-4466. http://www.ncbi.nlm.nih.gov/pubmed/?term=29067120
  15. Wang Y, Yang W, Zhao X, Zhang R. Experimental Study of the Protective Effect of Simvastatin on Lung Injury in Rats with Sepsis. Inflammation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29022140
  16. Tremoulet AH. Adjunctive therapies in Kawasaki disease. International journal of rheumatic diseases 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29076637
  17. An J, Shi F, Liu S et al. Preoperative statins as modifiers of cardiac and inflammatory outcomes following coronary artery bypass graft surgery: a meta-analysis. Interact Cardiovasc Thorac Surg 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29049804
  18. Rostami Z, Moteshaker Arani M, Salesi M et al. Effect of Statins on Patients and Graft Survival in Kidney Transplant Recipients: a Survival Meta-analysis. Iran J Kidney Dis 2017; 11:329-338. http://www.ncbi.nlm.nih.gov/pubmed/?term=29038386
  19. Carroll CB, Wyse RKH. Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson's Disease: Rationale for Clinical Trial, and Current Progress. Journal of Parkinson's disease 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29036837
  20. Hubert S, Chadwick A, Wacher V et al. Development of a Modified Release Formulation of Lovastatin Targeted to Intestinal Methanogens Implicated in Irritable Bowel Syndrome with Constipation. Journal of pharmaceutical sciences 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28989013
  21. Girardi G. Pravastatin to treat and prevent preeclampsia. Preclinical and clinical studies. Journal of reproductive immunology 2017; 124:15-20. http://www.ncbi.nlm.nih.gov/pubmed/?term=29028516
  22. Smit J, Lopez-Cortes LE, Thomsen RW et al. Statin Use and Risk of Community-Acquired Staphylococcus aureus Bacteremia: A Population-Based Case-Control Study. Mayo Clinic proceedings 2017; 92:1469-1478. http://www.ncbi.nlm.nih.gov/pubmed/?term=28982483
  23. Otten LA, van der Ven K, Kuhr M et al. Pravastatin for prevention of HELLP syndrome: A case report. Medicine (Baltimore) 2017; 96:e8229. http://www.ncbi.nlm.nih.gov/pubmed/?term=29049209
  24. Tang FC, Wang HY, Ma MM et al. Simvastatin attenuated rat thoracic aorta remodeling by decreasing ROCK2mediated CyPA secretion and CD147ERK1/2cyclin pathway. Mol Med Rep 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28983618
  25. Tulbah AS, Pisano E, Scalia S et al. Inhaled simvastatin nanoparticles for inflammatory lung disease. Nanomedicine (Lond) 2017; 12:2471-2485. http://www.ncbi.nlm.nih.gov/pubmed/?term=28972463
  26. Wang Y, Chen Q, Tan Q et al. Simvastatin accelerates hematoma resolution after intracerebral hemorrhage in a PPARgamma-dependent manner. Neuropharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29054366
  27. Yang J, Zhu Q, Liu Q et al. Statin use and endometrial cancer risk: a meta-analysis. Oncotarget 2017; 8:62425-62434. http://www.ncbi.nlm.nih.gov/pubmed/?term=28977956
  28. Alves-Cabratosa L, Garcia-Gil M, Comas-Cufi M et al. Statins and new-onset atrial fibrillation in a cohort of patients with hypertension. Analysis of electronic health records, 2006-2015. PLoS One 2017; 12:e0186972. http://www.ncbi.nlm.nih.gov/pubmed/?term=29073212
  29. Yeh YT, Yin WH, Tseng WK et al. Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? Data from a multicenter registry cohort study in Taiwan. PLoS One 2017; 12:e0186861. http://www.ncbi.nlm.nih.gov/pubmed/?term=29073192
  30. Archibugi L, Piciucchi M, Stigliano S et al. Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study. Scientific reports 2017; 7:13024. http://www.ncbi.nlm.nih.gov/pubmed/?term=29026148
  31. Fujiwara D, Tsubaki M, Takeda T et al. Statins induce apoptosis through inhibition of Ras signaling pathways and enhancement of Bim and p27 expression in human hematopoietic tumor cells. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2017; 39:1010428317734947. http://www.ncbi.nlm.nih.gov/pubmed/?term=28990465
  32. Zhdan V, Khaymenova G, Shilkina L et al. Determine the effectiveness of lipid-lowering therapy in patients with chronic obstructive pulmonary disease combined with coronary heart disease. Wiadomosci lekarskie (Warsaw, Poland : 1960) 2017; 70:303-305. http://www.ncbi.nlm.nih.gov/pubmed/?term=29059648

Primary Prevention

  1. Vallejo-Vaz AJ, Robertson M, Catapano AL et al. LDL-Cholesterol Lowering for the Primary Garshick M, Underberg JA. The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis. Curr Atheroscler Rep 2017; 19:48. http://www.ncbi.nlm.nih.gov/pubmed/?term=29038899
  2. Robinson T, Jackson R, Wells S et al. An observational study of how clinicians use cardiovascular risk assessment to inform statin prescribing decisions. The New Zealand medical journal 2017; 130:28-38. http://www.ncbi.nlm.nih.gov/pubmed/?term=28981492

Registry data

  1. Amrock SM, Duell PB, Knickelbine T et al. Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH patient registry. Atherosclerosis 2017; 267:19-26. http://www.ncbi.nlm.nih.gov/pubmed/?term=29080546
  2. Chung CM, Lin MS, Chang CH et al. Moderate to high intensity statin in dialysis patients after acute myocardial infarction: A national cohort study in Asia. Atherosclerosis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28985950
  3. Bock CH, Jay AM, Dyson G et al. The effect of genetic variants on the relationship between statins and breast cancer in postmenopausal women in the Women's Health Initiative observational study. Breast Cancer Res Treat 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29063981
  4. Murasato Y, Kinoshita Y, Yamawaki M et al. Effect of low-density lipoprotein cholesterol on the geometry of coronary bifurcation lesions and clinical outcomes of coronary interventions in the J-REVERSE registry. Cardiovascular intervention and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29052106
  5. Booth JN, 3rd, Colantonio LD, Chen L et al. Statin Discontinuation, Reinitiation, and Persistence Patterns Among Medicare Beneficiaries After Myocardial Infarction: A Cohort Study. Circ Cardiovasc Qual Outcomes 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=29021332
  6. Byrne DD, Tate JP, Forde KA et al. Risk of Acute Liver Injury After Statin Initiation by Human Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status. Clin Infect Dis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29020184
  7. Erlandson KM, Kitch D, Wester WC et al. The Impact of Statin and ACE-inhibitor/Angiotensin Receptor Blocker Therapy on Cognitive Function in Adults with HIV Infection. Clin Infect Dis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29020174
  8. Grudzinska FS, Dosanjh DP, Parekh D et al. Statin therapy in patients with community-acquired pneumonia. Clinical medicine (London, England) 2017; 17:403-407. http://www.ncbi.nlm.nih.gov/pubmed/?term=28974587
  9. M KS, Maroteau C, Veluchamy A et al. A common missense variant of LILRB5 is associated with statin intolerance and myalgia. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29020356
  10. Szummer K, Wallentin L, Lindhagen L et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29020314
  11. Schilling C, Knight J, Mortimer D et al. Australian general practitioners initiate statin therapy primarily on the basis of lipid levels; New Zealand general practitioners use absolute risk. Health Policy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29042060
  12. Leiter A, Bickell NA, LeRoith D et al. Statin Use and Breast Cancer Prognosis in Black and White Women. Hormones & cancer 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29052171
  13. Kaiser P, Arnold AM, Benkeser D et al. Comparing methods to address bias in observational data: statin use and cardiovascular events in a US cohort. International journal of epidemiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29024975
  14. Hickson RP, Robinson JG, Annis IE et al. Changes in Statin Adherence Following an Acute Myocardial Infarction Among Older Adults: Patient Predictors and the Association With Follow-Up With Primary Care Providers and/or Cardiologists. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=29051213
  15. Franklin JM, Donneyong MM, Desai RJ et al. Variation in adherence to medications across the healthcare system in two comparative effectiveness research cohorts. Journal of comparative effectiveness research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29039693
  16. Endo A, Okada T, Pak M et al. Comparison of the low-density lipoprotein cholesterol target value and the preventive effect of statins in elderly patients and younger patients. Journal of geriatric cardiology : JGC 2017; 14:383-391. http://www.ncbi.nlm.nih.gov/pubmed/?term=29056945
  17. Charlton J, Ravindrarajah R, Hamada S et al. Trajectory of Total Cholesterol in The Last Years of Life Over Age 80 Years. Cohort Study of 99,758 Participants. J Gerontol A Biol Sci Med Sci 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29028914
  18. Ceponiene I, Nakanishi R, Osawa K et al. Coronary Artery Calcium Progression Is Associated With Coronary Plaque Volume Progression: Results From a Quantitative Semiautomated Coronary Artery Plaque Analysis. JACC. Cardiovascular imaging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29055625
  19. Eymard F, Parsons C, Edwards MH et al. Statin use and knee osteoarthritis progression: Results from a post-hoc analysis of the SEKOIA trial. Joint Bone Spine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29037516
  20. Sim DS, Jeong MH. Differences in the Korea Acute Myocardial Infarction Registry Compared with Western Registries. Korean Circ J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29035427
  21. Smit J, Lopez-Cortes LE, Thomsen RW et al. Statin Use and Risk of Community-Acquired Staphylococcus aureus Bacteremia: A Population-Based Case-Control Study. Mayo Clinic proceedings 2017; 92:1469-1478. http://www.ncbi.nlm.nih.gov/pubmed/?term=28982483
  22. Robinson T, Jackson R, Wells S et al. An observational study of how clinicians use cardiovascular risk assessment to inform statin prescribing decisions. The New Zealand medical journal 2017; 130:28-38. http://www.ncbi.nlm.nih.gov/pubmed/?term=28981492
  23. Schaffer AL, Buckley NA, Pearson SA. Who benefits from fixed-dose combinations? Two-year statin adherence trajectories in initiators of combined amlodipine/atorvastatin therapy. Pharmacoepidemiol Drug Saf 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29067759
  24. Alves-Cabratosa L, Garcia-Gil M, Comas-Cufi M et al. Statins and new-onset atrial fibrillation in a cohort of patients with hypertension. Analysis of electronic health records, 2006-2015. PLoS One 2017; 12:e0186972. http://www.ncbi.nlm.nih.gov/pubmed/?term=29073212
  25. Yeh YT, Yin WH, Tseng WK et al. Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? Data from a multicenter registry cohort study in Taiwan. PLoS One 2017; 12:e0186861. http://www.ncbi.nlm.nih.gov/pubmed/?term=29073192
  26. Yum KS, Chang JY, Jeong WJ et al. Effect of statin on progression of symptomatic basilar artery stenosis and subsequent ischemic stroke. PLoS One 2017; 12:e0183798. http://www.ncbi.nlm.nih.gov/pubmed/?term=29020008
  27. Archibugi L, Piciucchi M, Stigliano S et al. Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study. Scientific reports 2017; 7:13024. http://www.ncbi.nlm.nih.gov/pubmed/?term=29026148
  28. Gaist D, Goldstein LB, Cea Soriano L, Garcia Rodriguez LA. Statins and the Risk of Intracerebral Hemorrhage in Patients With Previous Ischemic Stroke or Transient Ischemic Attack. Stroke 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29070714
  29. Myftiu S, Sulo E, Burazeri G et al. Clinical Profile and Management of Patients with Incident and Recurrent Acute Myocardial Infarction in Albania - a Call for More Focus on Prevention Strategies. Zdravstveno varstvo 2017; 56:236-243. http://www.ncbi.nlm.nih.gov/pubmed/?term=29062398

Renal Disease

  1. Chung CM, Lin MS, Chang CH et al. Moderate to high intensity statin in dialysis patients after acute myocardial infarction: A national cohort study in Asia. Atherosclerosis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28985950
  2. Thongnak L, Pongchaidecha A, Jaikumkao K et al. The additive effects of atorvastatin and insulin on renal function and renal organic anion transporter 3 function in diabetic rats. Scientific reports 2017; 7:13532. http://www.ncbi.nlm.nih.gov/pubmed/?term=29051569  

Reviews

  1. Price JC, Tien PC. Editorial: Statins and Liver Disease: Is it Time to Recommend Statins to Prevent Liver Disease Progression? Am J Gastroenterol 2017; 112:1506-1507. http://www.ncbi.nlm.nih.gov/pubmed/?term=28978973
  2. Wang HH, Garruti G, Liu M et al. Cholesterol and Lipoprotein Metabolism and Atherosclerosis: Recent Advances In reverse Cholesterol Transport. Annals of hepatology 2017; 16:21-36. http://www.ncbi.nlm.nih.gov/pubmed/?term=29080338
  3. El Khoury P, Elbitar S, Ghaleb Y et al. PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies. Curr Atheroscler Rep 2017; 19:49. http://www.ncbi.nlm.nih.gov/pubmed/?term=29038906
  4. Garshick M, Underberg JA. The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis. Curr Atheroscler Rep 2017; 19:48. http://www.ncbi.nlm.nih.gov/pubmed/?term=29038899
  5. Hylton Gravatt LA, Flurie RW, Lajthia E, Dixon DL. Clinical Guidance for Managing Statin and Antimicrobial Drug-Drug Interactions. Curr Atheroscler Rep 2017; 19:46. http://www.ncbi.nlm.nih.gov/pubmed/?term=28990114
  6. Leya M, Stone NJ. Statin Prescribing in the Elderly: Special Considerations. Curr Atheroscler Rep 2017; 19:47. http://www.ncbi.nlm.nih.gov/pubmed/?term=29019063
  7. Barkas F, Elisaf M. National hyperlipidemia management policies improve lipid target attainment in clinical practice. Current medical research and opinion 2017:1-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29019423
  8. Drakopoulou M, Toutouzas K, Michelongona A, Tousoulis D. Statins and vulnerable plaque. Current pharmaceutical design 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29065824
  9. Singh SP, Sashidhara KV. Lipid lowering agents of natural origin: An account of some promising chemotypes. European journal of medicinal chemistry 2017; 140:331-348. http://www.ncbi.nlm.nih.gov/pubmed/?term=28987600
  10. Bellosta S, Corsini A. Statin drug interactions and related adverse reactions: an update. Expert opinion on drug safety 2017:1-13. http://www.ncbi.nlm.nih.gov/pubmed/?term=29058944
  11. Roth EM. A Safety Evaluation of Evolocumab. Expert opinion on drug safety 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28988500
  12. Wu X, Song M, Qiu P et al. A metabolite of nobiletin, 4'-demethylnobiletin and atorvastatin synergistically inhibits human colon cancer cell growth by inducing G0/G1 cell cycle arrest and apoptosis. Food & function 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29063088
  13. Tremoulet AH. Adjunctive therapies in Kawasaki disease. International journal of rheumatic diseases 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29076637
  14. Kiyosue A. Nonfasting TG/HDL-C ratio seems a good predictor of MACE in CAD patients with statin therapy. Could it be a treatment target? J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29033056
  15. Ofori S, Dodiyi-Manuel S, Akpa MR. Comparison of 3 risk estimators to guide initiation of statin therapy for primary prevention of cardiovascular disease. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29050979
  16. Chastain DB, Stover KR, Riche DM. Evidence-based review of statin use in patients with HIV on antiretroviral therapy. Journal of clinical & translational endocrinology 2017; 8:6-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=29067253
  17. Girardi G. Pravastatin to treat and prevent preeclampsia. Preclinical and clinical studies. Journal of reproductive immunology 2017; 124:15-20. http://www.ncbi.nlm.nih.gov/pubmed/?term=29028516
  18. Hamilton-Craig CR, Chow CK, Younger JF et al. Cardiac Society of Australia and New Zealand position statement executive summary: coronary artery calcium scoring. Med J Aust 2017; 207:357-361. http://www.ncbi.nlm.nih.gov/pubmed/?term=29020908
  19. Schils E. [Lipid-lowering therapy in the elderly]. Revue medicale de Bruxelles 2017; 38:363-365. http://www.ncbi.nlm.nih.gov/pubmed/?term=28981241
  20. van de Borne P. [Recent progresses in the treatment of dyslipidemia]. Revue medicale de Bruxelles 2017; 38:357-360. http://www.ncbi.nlm.nih.gov/pubmed/?term=28981240
  21. Borges IBP, Silva MG, Misse RG, Shinjo SK. Lipid-lowering agent-triggered dermatomyositis and polymyositis: a case series and literature review. Rheumatology international 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29027009
  22. Balkanay OO, Omeroglu SN. [Approach to peripheral arterial disease in the elderly]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2017; 45:96-101. http://www.ncbi.nlm.nih.gov/pubmed/?term=28976393

Safety and side effects

  1. Taylor BA. Does Coenzyme Q10 Supplementation Mitigate Statin-Associated Muscle Symptoms? Pharmacological and Methodological Considerations. Am J Cardiovasc Drugs 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29027135
  2. Hassan SMS, Razzaque A, Ahmad Z et al. Does posttreatment thymoquinone reverse high-dose, atorvastatin-induced hepatic oxidative injury in rats? Canadian journal of physiology and pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28968507
  3. Williams SA, Murthy AC, DeLisle RK et al. Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28974520
  4. Bergland Ellingsen S, Nordmo E, Tore Lappegard K. Recurrence and Severe Worsening of Hepatotoxicity After Reintroduction of Atorvastatin in Combination With Ezetimibe. Clinical medicine insights. Case reports 2017; 10:1179547617731375. http://www.ncbi.nlm.nih.gov/pubmed/?term=28979175
  5. Hylton Gravatt LA, Flurie RW, Lajthia E, Dixon DL. Clinical Guidance for Managing Statin and Antimicrobial Drug-Drug Interactions. Curr Atheroscler Rep 2017; 19:46. http://www.ncbi.nlm.nih.gov/pubmed/?term=28990114
  6. Uchida M, Tajima Y, Kakuni M et al. Organic anion transporting polypeptides (OATPs)-mediated drug-drug interaction study between rosuvastatin and cyclosporine A in chimeric mice with humanized liver. Drug metabolism and disposition: the biological fate of chemicals 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29051147
  7. Huesch MD. Serious Adverse Events Among SPRINT Trial Participants Taking Statins at Baseline. Drugs in R&D 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29058304
  8. Sathyapalan T, Coady AM, Kilpatrick E, Atkin S. The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine connections 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29018156
  9. M KS, Maroteau C, Veluchamy A et al. A common missense variant of LILRB5 is associated with statin intolerance and myalgia. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29020356
  10. Marz W, Laufs U. Leucocyte immunoglobulin-like receptor subfamily-B5 (LILRB5) genetic variation and statin-associated muscle symptoms: another piece in a puzzling puzzle. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29059353
  11. Bellosta S, Corsini A. Statin drug interactions and related adverse reactions: an update. Expert opinion on drug safety 2017:1-13. http://www.ncbi.nlm.nih.gov/pubmed/?term=29058944
  12. Roth EM. A Safety Evaluation of Evolocumab. Expert opinion on drug safety 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28988500
  13. Ardeshna KP, Someshwar S, Rohatgi S, Jerajani HR. A Case of Psoriasis Vulgaris Aggravated with Atorvastatin, Aided by Concomitant Cyclosporine. Indian journal of dermatology 2017; 62:537-538. http://www.ncbi.nlm.nih.gov/pubmed/?term=28979024
  14. Abd El Aal HA, Ahmed LA, Hassan WA et al. Combination of carvacrol with simvastatin improves the lipid-lowering efficacy and alleviates simvastatin side effects. Journal of biochemical and molecular toxicology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29071762
  15. Allard NAE, Schirris TJJ, Verheggen RJ et al. Statins affect skeletal muscle performance: evidence for disturbances in energy metabolism. J Clin Endocrinol Metab 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29040646
  16. Shakir MKM, Shin T, Hoang TD, Mai VQ. Successful treatment of a patient with statin-induced myopathy and myotonic dystrophy type II with proprotein convertase subtilisin/kexin type 9 inhibitor, alirocumab (Praluent). J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29056268
  17. Buonuomo PS, Macchiaiolo M, Mastrogiorgio G et al. Statin-associated myopathy in pediatric settings: Myth or fact? J Pediatr 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28964429
  18. Rosenson RS, Larrey D, Waters DD, Olsson AG. RE: Praluent (Alirocumab)-Induced Renal Injury. Journal of pharmacy practice 2017:897190017734429. http://www.ncbi.nlm.nih.gov/pubmed/?term=28974137
  19. Eymard F, Parsons C, Edwards MH et al. Statin use and knee osteoarthritis progression: Results from a post-hoc analysis of the SEKOIA trial. Joint Bone Spine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29037516
  20. Rajput TA, Naveed AK, Farooqi ZR, Khan S. Effects of two functionally important SLCO1B1 gene polymorphisms on pharmacokinetics of atorvastatin. Pak J Pharm Sci 2017; 30:1363-1370. http://www.ncbi.nlm.nih.gov/pubmed/?term=29039339
  21. Leung YH, Turgeon J, Michaud V. Study of Statin- and Loratadine-Induced Muscle Pain Mechanisms Using Human Skeletal Muscle Cells. Pharmaceutics 2017; 9. http://www.ncbi.nlm.nih.gov/pubmed/?term=28994701
  22. Huang B, Zhou ZY, Li S et al. Tanshinone I prevents atorvastatin-induced cerebral hemorrhage in zebrafish and stabilizes endothelial cell-cell adhesion by inhibiting VE-cadherin internalization and actin-myosin contractility. Pharmacol Res 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29017932
  23. Borges IBP, Silva MG, Misse RG, Shinjo SK. Lipid-lowering agent-triggered dermatomyositis and polymyositis: a case series and literature review. Rheumatology international 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29027009
  24. Gaist D, Goldstein LB, Cea Soriano L, Garcia Rodriguez LA. Statins and the Risk of Intracerebral Hemorrhage in Patients With Previous Ischemic Stroke or Transient Ischemic Attack. Stroke 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29070714
  25. Park JB, Jung JH, Yoon YE et al. Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison with atorvastatin in patients with Metabolic syndrome (LESS-DM): study protocol for a randomized controlled trial. Trials 2017; 18:501. http://www.ncbi.nlm.nih.gov/pubmed/?term=29078817  

Stroke and CNS

  1. Liu H, Xu X. Effect of simvastatin in patients with aneurysmal subarachnoid hemorrhage: A systematic review and meta-analysis. The American journal of emergency medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28966073
  2. Shahbazi S, Kaur J, Kuanar A et al. Risk of Late-Onset Alzheimer's Disease by Plasma Cholesterol: Rational In Silico Drug Investigation of Pyrrole-Based HMG-CoA Reductase Inhibitors. Assay and drug development technologies 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29077483
  3. Kilic S, Sumerkan MC, Emren V et al. Secondary prevention of coronary heart disease in elderly population of turkey: A subgroup analysis of ELDERTURK study. Cardiology journal 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28980279
  4. Bohula EA, Wiviott SD, Giugliano RP et al. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients with Acute Coronary Syndrome in IMPROVE-IT. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28972004
  5. Erlandson KM, Kitch D, Wester WC et al. The Impact of Statin and ACE-inhibitor/Angiotensin Receptor Blocker Therapy on Cognitive Function in Adults with HIV Infection. Clin Infect Dis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29020174
  6. Rong X, Yin J, Wang H et al. Statin treatment may lower the risk of postradiation epilepsy in patients with nasopharyngeal carcinoma. Epilepsia 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29034463
  7. Wang Y, Chen Q, Tan Q et al. Simvastatin accelerates hematoma resolution after intracerebral hemorrhage in a PPARgamma-dependent manner. Neuropharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29054366
  8. Yum KS, Chang JY, Jeong WJ et al. Effect of statin on progression of symptomatic basilar artery stenosis and subsequent ischemic stroke. PLoS One 2017; 12:e0183798. http://www.ncbi.nlm.nih.gov/pubmed/?term=29020008
  9. Gaist D, Goldstein LB, Cea Soriano L, Garcia Rodriguez LA. Statins and the Risk of Intracerebral Hemorrhage in Patients With Previous Ischemic Stroke or Transient Ischemic Attack. Stroke 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29070714

Triglycerides/HDL

  1. Wang HH, Garruti G, Liu M et al. Cholesterol and Lipoprotein Metabolism and Atherosclerosis: Recent Advances In reverse Cholesterol Transport. Annals of hepatology 2017; 16:21-36. http://www.ncbi.nlm.nih.gov/pubmed/?term=29080338
  2. Ebtehaj S, Gruppen EG, Parvizi M et al. The anti-inflammatory function of HDL is impaired in type 2 diabetes: role of hyperglycemia, paraoxonase-1 and low grade inflammation. Cardiovascular diabetology 2017; 16:132. http://www.ncbi.nlm.nih.gov/pubmed/?term=29025405
  3. Huesch MD. Serious Adverse Events Among SPRINT Trial Participants Taking Statins at Baseline. Drugs in R&D 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29058304
  4. Kiyosue A. Nonfasting TG/HDL-C ratio seems a good predictor of MACE in CAD patients with statin therapy. Could it be a treatment target? J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29033056

Trials

  1. Hileman CO, McComsey GA. The Effect of Rosuvastatin on Vascular Disease Differs by Smoking Status in Treated HIV-Infection. AIDS research and human retroviruses 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28974102
  2. Howard TM, Bavishi AA, Stone NJ. A New HOPE? Lessons From HOPE-3. Am J Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29074093
  3. Betto M, Fares J, Saliba N, Ballout H. Efficacy and safety of a generic rosuvastatin in a real-world setting: prospective, observational clinical study in Lebanese patients. Annals of Saudi medicine 2017; 37:366-374. http://www.ncbi.nlm.nih.gov/pubmed/?term=28988251
  4. Dirajlal-Fargo S, El Kamari V, Sattar A et al. Effect of statin on arginine metabolites in treated HIV-infection. Atherosclerosis 2017; 266:74-80. http://www.ncbi.nlm.nih.gov/pubmed/?term=28992467
  5. Gitt AK, Lautsch D, Ferrieres J et al. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II. Atherosclerosis 2017; 266:158-166. http://www.ncbi.nlm.nih.gov/pubmed/?term=29028484
  6. Al-Salameh A, Bucher S, Bauduceau B et al. Gender-Related Differences in the Control of Cardiovascular Risk Factors in Primary Care for Elderly Patients with Type 2 Diabetes: A Cohort Study. Canadian journal of diabetes 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29037572
  7. Kilic S, Sumerkan MC, Emren V et al. Secondary prevention of coronary heart disease in elderly population of turkey: A subgroup analysis of ELDERTURK study. Cardiology journal 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28980279
  8. Ebtehaj S, Gruppen EG, Parvizi M et al. The anti-inflammatory function of HDL is impaired in type 2 diabetes: role of hyperglycemia, paraoxonase-1 and low grade inflammation. Cardiovascular diabetology 2017; 16:132. http://www.ncbi.nlm.nih.gov/pubmed/?term=29025405
  9. Fazio S, Robertson DG, Joh T et al. Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin. Cardiovasc Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29057618
  10. Gumbiner B, Joh T, Liang H et al. The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Deltaa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies. Cardiovasc Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29078037
  11. Ekanayaka RA, Rupasinha AD, Sooriyarachchi MR, Goonaratna C. The effect of thriphala, a herbal Ayurveda formulation, on serum lipids, in patients on a maintenance dose of atorvastatin for hyperlipidaemia: a randomized controlled trial. The Ceylon medical journal 2017; 62:128-140. http://www.ncbi.nlm.nih.gov/pubmed/?term=29072054
  12. Bohula EA, Wiviott SD, Giugliano RP et al. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients with Acute Coronary Syndrome in IMPROVE-IT. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28972004
  13. Huesch MD. Serious Adverse Events Among SPRINT Trial Participants Taking Statins at Baseline. Drugs in R&D 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29058304
  14. Rong X, Yin J, Wang H et al. Statin treatment may lower the risk of postradiation epilepsy in patients with nasopharyngeal carcinoma. Epilepsia 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29034463
  15. Koskinas KC, Siontis GCM, Piccolo R et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29069377
  16. Hu X, Cheng J, Li C. Effects of rosuvastatin and atorvastatin on nonsustained ventricular tachycardia in patients with ST-elevation myocardial infarction: a retrospective analysis. Eur J Clin Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28965256
  17. De Moreuil C, Le Mao R, Tromeur C et al. Association between statin exposure and venous thromboembolism risk in cancer patients. Data from the EDITH case-control study. Eur J Intern Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29046258
  18. Guo J, Zhang WZ, Zhao Q et al. Study on the effect of different doses of rosuvastatin on ventricular remodeling in patients with acute coronary syndrome after emergency percutaneous coronary intervention. Eur Rev Med Pharmacol Sci 2017; 21:4457-4463. http://www.ncbi.nlm.nih.gov/pubmed/?term=29077146
  19. Zhang T, Shao B, Liu GA. Rosuvastatin promotes the differentiation of peripheral blood monocytes into M2 macrophages in patients with atherosclerosis by activating PPAR-gamma. Eur Rev Med Pharmacol Sci 2017; 21:4464-4471. http://www.ncbi.nlm.nih.gov/pubmed/?term=29077145
  20. Webster R, Bullen C, Patel A et al. Impact of switching to polypill based therapy by baseline potency of medication: Post-hoc analysis of the SPACE Collaboration dataset. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28986058
  21. Bayes-Genis A, Nunez J, Zannad F et al. The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIOSTAT-CHF Subanalysis. J Am Coll Cardiol 2017; 70:2128-2136. http://www.ncbi.nlm.nih.gov/pubmed/?term=29050560
  22. Allard NAE, Schirris TJJ, Verheggen RJ et al. Statins affect skeletal muscle performance: evidence for disturbances in energy metabolism. J Clin Endocrinol Metab 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29040646
  23. Haywood LJ, Davis BR, Piller LB et al. Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT. Journal of the National Medical Association 2017; 109:172-181. http://www.ncbi.nlm.nih.gov/pubmed/?term=28987246
  24. Vaidya K, Arnott C, Martinez GJ et al. Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome: A CT Coronary Angiography Study. JACC. Cardiovascular imaging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29055633
  25. Arrieta A, Hong JC, Khera R et al. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29049467
  26. Otten LA, van der Ven K, Kuhr M et al. Pravastatin for prevention of HELLP syndrome: A case report. Medicine (Baltimore) 2017; 96:e8229. http://www.ncbi.nlm.nih.gov/pubmed/?term=29049209
  27. Tulbah AS, Pisano E, Scalia S et al. Inhaled simvastatin nanoparticles for inflammatory lung disease. Nanomedicine (Lond) 2017; 12:2471-2485. http://www.ncbi.nlm.nih.gov/pubmed/?term=28972463
  28. Park JB, Jung JH, Yoon YE et al. Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison with atorvastatin in patients with Metabolic syndrome (LESS-DM): study protocol for a randomized controlled trial. Trials 2017; 18:501. http://www.ncbi.nlm.nih.gov/pubmed/?term=29078817
  29. Zhdan V, Khaymenova G, Shilkina L et al. Determine the effectiveness of lipid-lowering therapy in patients with chronic obstructive pulmonary disease combined with coronary heart disease. Wiadomosci lekarskie (Warsaw, Poland : 1960) 2017; 70:303-305. http://www.ncbi.nlm.nih.gov/pubmed/?term=29059648

Women and elderly

  1. Greenlee H, Strizich G, Lovasi GS et al. Concordance with prevention guidelines and subsequent cancer, cardiovascular disease, and mortality: A longitudinal study of older adults. American journal of epidemiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29020206
  2. Bock CH, Jay AM, Dyson G et al. The effect of genetic variants on the relationship between statins and breast cancer in postmenopausal women in the Women's Health Initiative observational study. Breast Cancer Res Treat 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29063981
  3. Al-Salameh A, Bucher S, Bauduceau B et al. Gender-Related Differences in the Control of Cardiovascular Risk Factors in Primary Care for Elderly Patients with Type 2 Diabetes: A Cohort Study. Canadian journal of diabetes 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29037572
  4. Kilic S, Sumerkan MC, Emren V et al. Secondary prevention of coronary heart disease in elderly population of turkey: A subgroup analysis of ELDERTURK study. Cardiology journal 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28980279
  5. Kleipool EEF, Peters MJL, Muller M. Letter by Kleipool et al Regarding Article, "Primary Prevention With Statin Therapy in the Elderly: New Meta-Analyses From the Contemporary JUPITER and HOPE-3 Randomized Trials". Circulation 2017; 136:1456-1457. http://www.ncbi.nlm.nih.gov/pubmed/?term=28993377
  6. Vos E, Biron P, Rose CP. Letter by Vos et al Regarding Article, "Primary Prevention With Statin Therapy in the Elderly: New Meta-Analyses From the Contemporary JUPITER and HOPE-3 Randomized Trials". Circulation 2017; 136:1454-1455. http://www.ncbi.nlm.nih.gov/pubmed/?term=28993376
  7. Leya M, Stone NJ. Statin Prescribing in the Elderly: Special Considerations. Curr Atheroscler Rep 2017; 19:47. http://www.ncbi.nlm.nih.gov/pubmed/?term=29019063
  8. Leiter A, Bickell NA, LeRoith D et al. Statin Use and Breast Cancer Prognosis in Black and White Women. Hormones & cancer 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29052171
  9. Zullo AR, Sharmin S, Lee Y et al. Secondary Prevention Medication Use After Myocardial Infarction in U.S. Nursing Home Residents. J Am Geriatr Soc 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29044457
  10. Endo A, Okada T, Pak M et al. Comparison of the low-density lipoprotein cholesterol target value and the preventive effect of statins in elderly patients and younger patients. Journal of geriatric cardiology : JGC 2017; 14:383-391. http://www.ncbi.nlm.nih.gov/pubmed/?term=29056945
  11. Charlton J, Ravindrarajah R, Hamada S et al. Trajectory of Total Cholesterol in The Last Years of Life Over Age 80 Years. Cohort Study of 99,758 Participants. J Gerontol A Biol Sci Med Sci 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29028914
  12. Girardi G. Pravastatin to treat and prevent preeclampsia. Preclinical and clinical studies. Journal of reproductive immunology 2017; 124:15-20. http://www.ncbi.nlm.nih.gov/pubmed/?term=29028516
  13. Otten LA, van der Ven K, Kuhr M et al. Pravastatin for prevention of HELLP syndrome: A case report. Medicine (Baltimore) 2017; 96:e8229. http://www.ncbi.nlm.nih.gov/pubmed/?term=29049209
  14. Schils E. [Lipid-lowering therapy in the elderly]. Revue medicale de Bruxelles 2017; 38:363-365. http://www.ncbi.nlm.nih.gov/pubmed/?term=28981241
  15. Balkanay OO, Omeroglu SN. [Approach to peripheral arterial disease in the elderly]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2017; 45:96-101. http://www.ncbi.nlm.nih.gov/pubmed/?term=28976393
  16. Yildirim AB, Kilinc AY. [Dyslipidaemias in elderly patients]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2017; 45:25-28. http://www.ncbi.nlm.nih.gov/pubmed/?term=28976376

 
 

Twitter
IAS Website
For information
You are now on the editors mailing list of the IAS Statin Newsletter.
The IAS Statin Newsletter is part of the IAS News and Literature update service.
 
This activity is supported by an educational grant from Pfizer.